Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of BridgeBio Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001743881.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
16 Aug 2026
- Public ticker
- BBIO on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
16 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001743881
- Issuer location
- Palo Alto, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BridgeBio Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
16 Aug 2026
13D/G
13F
3/4/5
Lead comparable stake: 6.8%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 6.8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
6.8%
FARALLON CAPITAL MANAGEMENT, L.L.C.
5.5%
Farallon Capital Partners, L.P.
5.2%
VIKING GLOBAL INVESTORS LP
5%
BlackRock, Inc.
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
6.8%
|
$977,092,024
13,179,013 shares
|
+$161,518,142 | 31 Mar 2026 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
5.5%
|
$836,992,038
10,743,063 shares
|
$0 | 30 Jun 2026 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
5.2%
|
$674,408,855
10,226,063 shares
|
$0 | 22 May 2026 |
| VIKING GLOBAL INVESTORS LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
5%
from 13D/G
|
$816,436,500
18,555,375 shares
|
— | 27 Jun 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$782,601,148
12,441,196 shares
mixed-class rows
|
— | 30 Jun 2026 |
| KKR Genetic Disorder L.P. |
13D/G
3/4/5
KKR Group Partnership L.P. · 10%+ Owner
|
4.7%
|
$719,322,695
9,232,739 shares
|
-$313,839,555 | 13 Aug 2026 |
| Neil Kumar |
13D/G
3/4/5
Chief Executive Officer, Director
|
4.6%
|
$689,354,243
9,282,982 shares
|
-$87,903,790 | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
1.1%
from 13D/G
|
$130,868,000
2,026,383 shares
mixed-class rows
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$130,163,349.
Buys
$0
Insiders: 0
Sells
$130,163,349
Insiders: 10
Net
-$130,163,349
Shares: -1,893,551
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 1,893,551
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 427,343 | $0 | $33,004,646 | -$33,004,646 |
| 3-6 | 0 | 365,346 | $0 | $25,213,262 | -$25,213,262 |
| 6-9 | 0 | 351,658 | $0 | $25,749,833 | -$25,749,833 |
| 9-12 | 0 | 749,204 | $0 | $46,195,608 | -$46,195,608 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to BridgeBio Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
VIKING GLOBAL INVESTORS LP
Net 12M change
-$130,163,348
Latest report
18 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $816,436,500 | Filing P/S | 27 Jun 2025 | ||
| KKR Genetic Disorder L.P. | 10%+ Owner | $453,525,208 | Filing P/S | 12 May 2025 | ||
| Neil Kumar | Chief Executive Officer, Director | $391,357,419 | -$65,022,695 | -14% | Mixed | 18 Aug 2026 |
| Charles J. Homcy | Director | $68,309,991 | Mixed | 22 Jun 2026 | ||
| Frank Mccormick | Director | $56,975,538 | -$17,246,737 | -23% | Mixed | 22 Jun 2026 |
| Thomas Trimarchi | President and CFO | $25,064,679 | -$3,029,971 | -11% | Median | 16 Aug 2026 |
| Ali J. Satvat | Director | $12,622,937 | Mixed | 22 Jun 2026 | ||
| Maricel Apuli | Chief Accounting Officer | $9,137,727 | -$621,698 | -6.4% | Median | 16 Aug 2026 |
| James C. Momtazee | Director | $7,356,938 | Mixed | 22 Jun 2026 | ||
| Brian C. Stephenson | CFO and Treasurer | $6,443,801 | Mixed | 25 Feb 2025 | ||
| Andrew Lo | Director | $5,098,839 | -$6,319,662 | -55% | Mixed | 22 Jun 2026 |
| Richard H. Scheller | Director | $2,421,359 | Mixed | 16 Feb 2023 | ||
| Douglas A. Dachille | Director | $2,270,796 | Mixed | 22 Jun 2026 | ||
| Fred Hassan | Director | $2,218,814 | Mixed | 22 Jun 2026 | ||
| Andrea Ellis | Director | $1,896,636 | -$5,653,330 | -75% | Filing P/S | 09 Jul 2026 |
| Ronald J. Daniels | Director | $1,558,049 | -$3,888,999 | -71% | Mixed | 22 Jun 2026 |
| Randal W. Scott | Director | $1,098,071 | -$2,092,477 | -66% | Mixed | 15 May 2026 |
| Eric Aguiar | Director | $785,596 | Mixed | 22 Jun 2026 | ||
| Jennifer E. Cook | Director | $754,470 | -$21,920,435 | -97% | Filing P/S | 09 Jul 2026 |
| Hannah Valantine | Director | $664,444 | -$4,367,344 | -87% | Mixed | 22 Jun 2026 |
Recent insider transactions for BridgeBio Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Neil Kumar | BBIO | Common Stock | Sale | -1.94% | $840,257 | $84.03 | -10,000 | 505,686 | 19 Aug 2026 | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. |
| Neil Kumar | BBIO | Common Stock | Sale | -12.6% | $2,886,994 | $82.53 | -34,980 | 243,327 | 18 Aug 2026 | Direct |
| Thomas Trimarchi | BBIO | Common Stock | Tax liability | -6.34% | -22,781 | 336,529 | 16 Aug 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Tax liability | -11.5% | -36,237 | 278,307 | 16 Aug 2026 | Direct | ||
| Neil Kumar | BBIO | Common Stock | Options Exercise | 29.3% | 71,217 | 314,544 | 16 Aug 2026 | Direct | ||
| Neil Kumar | BBIO | Restricted Stock Units | Options Exercise | -51.5% | -71,217 | 67,088 | 16 Aug 2026 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Tax liability | -3.7% | -4,714 | 122,687 | 16 Aug 2026 | Direct | ||
| Maricel Apuli | BBIO | Common Stock | Sale | -1.55% | $160,120 | $80.06 | -2,000 | 127,401 | 30 Jul 2026 | Direct |
| Andrea Ellis | BBIO | Common Stock | Sale | -43.2% | $1,442,028 | $84.00 | -17,167 | 22,579 | 09 Jul 2026 | Direct |
| Andrea Ellis | BBIO | Common Stock | Options Exercise | 76% | 17,167 | 39,746 | 09 Jul 2026 | Direct | ||
| Andrea Ellis | BBIO | Stock Option (right to buy) | Options Exercise | -50% | -17,167 | 17,167 | 09 Jul 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Common Stock | Sale | -94.7% | $13,156,008 | $88.54 | -148,589 | 8,383 | 09 Jul 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Options Exercise | 1772.5% | 148,589 | 156,972 | 09 Jul 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Options Exercise | -100% | -148,589 | 0 | 09 Jul 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Common Stock | Sale | -81.6% | $2,601,690 | $70.00 | -37,167 | 8,383 | 24 Jun 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Options Exercise | 443.4% | 37,167 | 45,550 | 24 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Options Exercise | -68.4% | -37,167 | 17,167 | 24 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Common Stock | Sale | -20.8% | $150,580 | $68.57 | -2,196 | 8,383 | 23 Jun 2026 | Direct |
| Hannah Valantine | BBIO | Common Stock | Sale | -19.2% | $150,580 | $68.57 | -2,196 | 9,259 | 23 Jun 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Hannah Valantine | BBIO | Common Stock | Sale | -19.7% | $190,944 | $68.00 | -2,808 | 11,455 | 22 Jun 2026 | Direct |
| Hannah Valantine | BBIO | Common Stock | Options Exercise | 24.5% | 2,808 | 14,263 | 22 Jun 2026 | Direct | ||
| Hannah Valantine | BBIO | Common Stock | Award | 53.4% | 3,990 | 11,455 | 22 Jun 2026 | Direct | ||
| Hannah Valantine | BBIO | Stock Option (Right to Buy) | Options Exercise | -33.3% | -2,808 | 5,617 | 22 Jun 2026 | Direct | ||
| Hannah Valantine | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Andrew Lo | BBIO | Common Stock | Award | 28.3% | 3,990 | 18,079 | 22 Jun 2026 | Direct | ||
| Andrew Lo | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Charles J. Homcy | BBIO | Common Stock | Award | 0.44% | 3,990 | 919,876 | 22 Jun 2026 | Direct | ||
| Charles J. Homcy | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Eric Aguiar | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Eric Aguiar | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Ronald J. Daniels | BBIO | Common Stock | Award | 23.5% | 3,990 | 20,981 | 22 Jun 2026 | Direct | ||
| Ronald J. Daniels | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Andrea Ellis | BBIO | Common Stock | Award | 21.5% | 3,990 | 22,579 | 22 Jun 2026 | Direct | ||
| Andrea Ellis | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Fred Hassan | BBIO | Common Stock | Award | 15.4% | 3,990 | 29,879 | 22 Jun 2026 | Direct | ||
| Fred Hassan | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| James C. Momtazee | BBIO | Common Stock | Award | 26.5% | 3,990 | 19,070 | 22 Jun 2026 | Direct | ||
| James C. Momtazee | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Frank Mccormick | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Frank Mccormick | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Douglas A. Dachille | BBIO | Common Stock | Award | 60.6% | 3,990 | 10,579 | 22 Jun 2026 | Direct | ||
| Douglas A. Dachille | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Ali J. Satvat | BBIO | Common Stock | Award | 2.4% | 3,990 | 169,983 | 22 Jun 2026 | Direct | ||
| Ali J. Satvat | BBIO | Stock Option (Right to Buy) | Award | 5,277 | 5,277 | 22 Jun 2026 | Direct | |||
| Charles J. Homcy | BBIO | Common Stock | Tax liability | -0.09% | -788 | 915,886 | 20 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Common Stock | Sale | -93.2% | $6,012,157 | $66.62 | -90,240 | 6,589 | 15 Jun 2026 | Direct |
| Jennifer E. Cook | BBIO | Common Stock | Options Exercise | 604.7% | 83,088 | 96,829 | 15 Jun 2026 | Direct | ||
| Jennifer E. Cook | BBIO | Stock Option (Right to Buy) | Options Exercise | -70.8% | -83,088 | 34,334 | 15 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.